Drug Profile
Research programme: haemophilia type A therapies - In2Gen
Alternative Names: 12GDBN; Haemophilia type A therapies research programme - In2GenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator In2Gen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in South Korea
- 17 Aug 2005 This programme is available for licensing (http://www.in2gen.com)
- 17 Aug 2005 Preclinical trials in Haemophilia A in South Korea (unspecified route)